ADRB2 and non-small cell lung carcinoma: Moreover, it has been demonstrated that EGFR inhibitor resistance in NSCLC (Non-Small-Cell Lung Carcinoma) correlates with the activation of the β2-AR pathway through an IL-6 dependent mechanism16.